Luca Gianni Selected Research

Lapatinib (GW572016)

1/2017	Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
11/2012	Trastuzumab emtansine for HER2-positive advanced breast cancer.
11/2011	Treatment of HER2-positive breast cancer: current status and future perspectives.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Luca Gianni Research Topics

Disease

76	Breast Neoplasms (Breast Cancer) 01/2023 - 01/2002
41	Neoplasms (Cancer) 12/2023 - 07/2002
11	Triple Negative Breast Neoplasms 02/2024 - 01/2011
11	Pathologic Complete Response 01/2023 - 10/2005
11	Cardiotoxicity 02/2009 - 01/2002
8	Neutropenia 01/2021 - 03/2005
6	Disease Progression 01/2021 - 10/2004
5	Adenocarcinoma 01/2020 - 07/2016
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2019 - 06/2003
4	Brain Neoplasms (Brain Tumor) 06/2022 - 01/2016
4	Febrile Neutropenia 01/2021 - 05/2013
4	Fatigue 10/2018 - 10/2013
4	Inflammatory Breast Neoplasms 06/2016 - 01/2010
4	Heart Failure 01/2010 - 06/2004
3	Carcinoma (Carcinomatosis) 10/2020 - 03/2005
3	Thrombocytopenia (Thrombopenia) 01/2017 - 11/2012
2	Hypersensitivity (Allergy) 01/2023 - 01/2018
2	Diarrhea 01/2021 - 11/2012
2	Carcinogenesis 10/2020 - 01/2002
2	Lung Neoplasms (Lung Cancer) 12/2018 - 01/2018
2	Stomatitis 01/2018 - 05/2014
2	Neoplasm Metastasis (Metastasis) 01/2016 - 12/2010
2	Vomiting 10/2013 - 11/2012
2	Nausea 10/2013 - 11/2012
2	Cardiomyopathies (Cardiomyopathy) 01/2007 - 06/2004
2	Ovarian Neoplasms (Ovarian Cancer) 03/2005 - 06/2003
1	Anaphylaxis (Anaphylactic Shock) 01/2023
1	Anemia 01/2021
1	Leukopenia 01/2021
1	Brain Diseases (Brain Disorder) 03/2019

Drug/Important Bio-Agent (IBA)

41	Trastuzumab (Herceptin)FDA Link 01/2023 - 01/2002
16	human ERBB2 proteinIBA 02/2024 - 03/2010
15	pertuzumabIBA 01/2023 - 03/2010
15	AnthracyclinesIBA 10/2022 - 01/2002
13	ErbB Receptors (EGF Receptor)IBA 01/2023 - 07/2002
13	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2014 - 01/2003
12	Paclitaxel (Taxol)FDA LinkGeneric 03/2018 - 01/2003
9	Capecitabine (Xeloda)FDA Link 08/2022 - 10/2006
9	Docetaxel (Taxotere)FDA Link 01/2017 - 07/2006
8	Biomarkers (Surrogate Marker)IBA 01/2023 - 02/2008
8	taxaneIBA 10/2022 - 03/2005
7	Ado-Trastuzumab EmtansineIBA 01/2023 - 11/2012
7	Estrogen ReceptorsIBA 01/2022 - 12/2005
7	Fluorouracil (Carac)FDA LinkGeneric 01/2014 - 05/2004
7	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2014 - 05/2004
7	Methotrexate (Mexate)FDA LinkGeneric 01/2014 - 05/2004
6	Immunoconjugates (Immunoconjugate)IBA 02/2024 - 04/2015
6	Hormones (Hormone)IBA 01/2023 - 12/2010
5	Taxoids (Taxanes)IBA 10/2022 - 10/2004
5	Gemcitabine FDA Link 08/2022 - 07/2016
5	ParaffinIBA 02/2019 - 10/2005
5	Cisplatin (Platino)FDA LinkGeneric 10/2018 - 10/2013
5	Monoclonal AntibodiesIBA 01/2017 - 01/2002
4	sacituzumab govitecanIBA 01/2023 - 01/2021
4	Vinorelbine (Navelbine)FDA LinkGeneric 08/2022 - 01/2011
4	Estrogens (Estrogen)FDA Link 01/2022 - 01/2013
4	Formaldehyde (Formol)FDA Link 02/2019 - 01/2014
4	130-nm albumin-bound paclitaxelIBA 10/2018 - 07/2016
4	Epirubicin (Ellence)FDA LinkGeneric 06/2012 - 06/2004
3	Phenobarbital (Luminal)FDA Link 12/2023 - 12/2010
3	Immune Checkpoint InhibitorsIBA 09/2023 - 01/2018
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 10/2020
3	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2014
3	LigandsIBA 01/2021 - 04/2007
3	Lapatinib (GW572016)FDA Link 01/2017 - 11/2011
3	Transaminases (Aminotransferases)IBA 10/2013 - 03/2005
3	Tyrosine Kinase InhibitorsIBA 02/2004 - 01/2002
2	Surface Antigens (Surface Antigen)IBA 02/2024 - 01/2021
2	eribulin FDA Link 08/2022 - 01/2021
2	palbociclibIBA 01/2022 - 01/2018
2	IntegrinsIBA 02/2019 - 01/2017
2	DNA (Deoxyribonucleic Acid)IBA 02/2019 - 01/2019
2	AntibodiesIBA 01/2017 - 04/2007
2	Progesterone Receptors (Progesterone Receptor)IBA 06/2016 - 01/2011
2	Bevacizumab (Avastin)FDA Link 01/2016 - 05/2013
2	Cytotoxins (Cytolysins)IBA 04/2015 - 10/2004
2	Everolimus FDA Link 05/2014 - 01/2011
2	TrabectedinIBA 10/2013 - 03/2005
2	ProdrugsIBA 10/2010 - 10/2006
2	IronIBA 01/2008 - 06/2004
2	quinone (benzoquinone)IBA 01/2008 - 04/2006
2	Free RadicalsIBA 01/2008 - 06/2004
2	adriamycinolIBA 02/2007 - 07/2006
2	Gefitinib (Iressa)FDA Link 02/2004 - 06/2003
1	Granzymes (Granzyme)IBA 09/2023
1	Cyclin D1IBA 01/2022
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2022
1	Neuregulin-1 (Neuregulin 1)IBA 01/2021
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2021
1	Conditioned Culture MediaIBA 01/2021
1	Topoisomerase I InhibitorsIBA 01/2021

Therapy/Procedure

44	Therapeutics 12/2023 - 06/2003
37	Drug Therapy (Chemotherapy) 02/2024 - 11/2004
17	Neoadjuvant Therapy 01/2023 - 01/2010
5	Adjuvant Chemotherapy 06/2022 - 10/2005
4	Immunotherapy 09/2023 - 01/2018
2	Salvage Therapy 01/2022 - 03/2005
2	Radiotherapy 01/2018 - 07/2014
1	Subcutaneous Injections 01/2023
1	Duration of Therapy 01/2020